What we know about surgical therapy in early-stage non-small-cell lung cancer: a guide for the medical oncologist
Sassine Ghanem,1 Sandy El Bitar,1 Sami Hossri,1 Chanudi Weerasinghe,2 Jean Paul Atallah2 1Department of Internal Medicine, 2Department of Hematology and Oncology, Staten Island University Hospital – Northwell Health, New York, NY, USA Abstract: Lung cancer remains the leading cause of deat...
Main Authors: | Ghanem S, El Bitar S, Hossri S, Weerasinghe C, Atallah JP |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2017-07-01
|
Series: | Cancer Management and Research |
Subjects: | |
Online Access: | https://www.dovepress.com/what-we-know-about-surgical-therapy-in-early-stage-non-small-cell-lung-peer-reviewed-article-CMAR |
Similar Items
-
Lobectomy offers improved survival outcomes relative to segmentectomy for >2 but ≤4 cm non–small cell lung cancer tumorsCentral MessagePerspective
by: Terrance Peng, MD, MPH, et al.
Published: (2022-06-01) -
Thoracoscopic segmentectomy versus lobectomy: A propensity score–matched analysisCentral MessagePerspective
by: Julio Sesma, MD, et al.
Published: (2022-03-01) -
Surgeons' preference sublobar resection for stage I NSCLC less than 3 cm
by: Chien‐Sheng Huang, et al.
Published: (2020-04-01) -
Comparison of outcomes following lobectomy, segmentectomy, and wedge resection based on pathological subtyping in patients with pN0 invasive lung adenocarcinoma ≤1 cm
by: Weijian Song, et al.
Published: (2022-12-01) -
Sublobar Resection for Early-Stage Lung Cancer: An Oncologically Valid Procedure?
by: Ian Diebels, et al.
Published: (2023-04-01)